Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial

Table 3 Changes from baseline in physical activity parameters at Week 3 (ITT population)

Parameter	Placebo (n = 83^a)	Aclidinium 400 μg BID (n = 85^a)	Treatment difference vs placebo (95% CI)
Step count (steps per day)	-163.2 (226.1)	295.8 (223.7)	459.0 (-61.8, 979.8)
Duration of activity of at least moderate intensity^b (min/day)	-5.9 (4.1)	4.2 (4.1)	10.1 (2.0, 18.2)^*
Physical activity level^c	-0.006 (0.013)	0.018 (0.013)^d	0.024 (-0.003, 0.051)
Daily active energy expenditure >3 metabolic equivalents (kcal/day)	-32.7 (21.0)	21.9 (20.8)	54.5 (13.3, 95.8)^*

Data reported as least squares means (standard error) change from baseline (analysis of covariance).
^*p < 0.05 versus placebo.
^an = number of patients who had ≥5 days with ≥22 h of valid data and were included in the analyses.
^bAny physical activity >3 metabolic equivalents.
^cRatio calculated as the total daily energy expenditure divided by the whole of the night sleeping energy expenditure.
^dn = 84.
BID, twice daily; CI, confidence interval; ITT, intent-to-treat.

ISSN: 1471-2466